<DOC>
	<DOCNO>NCT01002768</DOCNO>
	<brief_summary>This trial i conduct Europe . The aim clinical trial evaluate hypoglycaemic response ( response low blood sugar ) NN1250 ( insulin degludec ) subject type 1 diabetes . The trial design two-period , crossover trial trial participant randomise one two treatment period .</brief_summary>
	<brief_title>Comparison Hypoglycaemic Response Between NN1250 Insulin Glargine Type 1 Diabetics</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Type 1 diabetes mellitus ( diagnose clinically ) least 12 month Body mass index 18.028.0 kg/m^2 ( inclusive ) Use insulin glargine within 3 month prior first dose investigational product trial Subject donate blood plasma past month 500 mL within 3 month prior screen Smoker Recurrent severe hypoglycaemia ( 1 severe hypoglycaemic event last 12 month )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>